Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorderReuters • 03/27/26
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)Business Wire • 03/27/26
Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/06/26
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advancesProactive Investors • 03/03/26
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent ProgressBusiness Wire • 02/26/26
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/26
Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon ProgramSeeking Alpha • 12/26/25
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare ConferenceBusiness Wire • 11/25/25
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressBusiness Wire • 11/06/25
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 10/23/25
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For StockBenzinga • 10/14/25
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)Business Wire • 10/14/25
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 10/10/25
Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorderReuters • 10/03/25
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law FirmPRNewsWire • 09/19/25
Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease StudyZacks Investment Research • 08/21/25
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.Barrons • 08/20/25